-
How to patent targeted therapy pharmaceuticals in ChinaAug 07 2024How to patent targeted therapy pharmaceuticals in ChinaMiranda Xie, 7 August 2024, first published by IAMPrecis: The CNIPA’s examination practice when it comes to targeted therapy drugs is tightening, with examiners increasingly inclined to reject claims...Aug 07 2024 -
What applicants need to know about partial design examinatio...July 25 2024What applicants need to know about partial design examination in ChinaLi Han, first published by WTR• Although design patent applications are not subject to substantive examination, partial design applicants could still meet objections• A design patent application must ...July 25 2024 -
Patenting AI-driven drug compound screening inventions in Ch...July 05 2024Patenting AI-driven drug compound screening inventions in ChinaThe integration of AI in drug discovery, particularly in the screening of drug compounds, ushers in seismic change to the pharmaceutical industry. AI technologies, especially machine learning and deep...July 05 2024 -
China’s SPC offers guidance on identifying technical proble...May 23 2024China’s SPC offers guidance on identifying technical problems actually solved in inventiveness assessmentsThe non-obviousness of a claimed invention to persons skilled in the art hinges on whether the prior art provides motivation for applying the distinguishing features of the invention to the closest pr...May 23 2024 -
CNIPA clarifies examination rule over an inventiveness asses...Apr 08 2024CNIPA clarifies examination rule over an inventiveness assessment step (2024)Since non-obviousness of the invention is benchmarked against the closest prior art and the technical problem actually solved by the invention, should the technical problem be defined in an overly bro...Apr 08 2024 -
CNIPA offers guidance on validity assessments of siRNA paten...Mar 12 2024CNIPA offers guidance on validity assessments of siRNA patentsRibonucleic acid interference (RNAi) refers to the biological mechanism wherein messenger RNA degradation is triggered by double-stranded small interfering RNAs (siRNA) with complementary sequences, l...Mar 12 2024 -
Supreme People’s Court offers much-needed guidance followin...Jan 24 2024Supreme People’s Court offers much-needed guidance following high-profile monopoly dispute involving pharma patentsIn one of China’s “Ten Exemplary Anti-monopoly and Unfair Competition Cases of 2023” (a list that was released on 14 September 2023), the Supreme People’s Court has elucidated the correlation betw...Jan 24 2024 -
New guidelines for the patent term extension regime in ChinaJan 19 2024New guidelines for the patent term extension regime in ChinaThe fourth amendment to China’s Patent Law (Article 42) introduced a patent term extension (PTE) regime in China. The newly revised Implementing Regulations of the Patent Law and the Guidelines for P...Jan 19 2024 -
How amended regulations to China’s Patent Law will impact t...Jan 10 2024How amended regulations to China’s Patent Law will impact the IP landscapeOn 21 December 2023 China’s State Council promulgated the long-awaited “Decision on Amending the Implementing Regulations of the Patent Law of the People’s Republic of China”. The amended regulati...Jan 10 2024 -
Strategies for patenting personalised medicine and companion...Dec 05 2023Strategies for patenting personalised medicine and companion diagnostics in ChinaXIE Minnan, first published by MIPPersonalised medicine, which is generally considered analogous to precision medicine, is built on companion diagnostics. A companion diagnostic is a medical device, o...Dec 05 2023 -
CNIPA guidance on the support of pharmaceutical use patent c...Sept 07 2023CNIPA guidance on the support of pharmaceutical use patent claims (2023)Article 26.4 of China’s Patent Law prescribes that “claims shall be supported by the specification and shall define the extent of the patent protection sought for in a clear and concise manner”. Th...Sept 07 2023 -
CNIPA deals a heavy blow to AbbVie’s upadacitinib patent po...Aug 10 2023CNIPA deals a heavy blow to AbbVie’s upadacitinib patent portfolio (2023)On August 10 2023, the China National Intellectual Property Administration (CNIPA) issued two invalidation decisions, No. 561725 (Decision #1) and No. 562232 (Decision #2), in response to invalidity r...Aug 10 2023